Last reviewed · How we verify
CHF 5188 pMDI — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
CHF 5188 pMDI (CHF 5188 pMDI) — Chiesi Farmaceutici S.p.A..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CHF 5188 pMDI TARGET | CHF 5188 pMDI | Chiesi Farmaceutici S.p.A. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CHF 5188 pMDI CI watch — RSS
- CHF 5188 pMDI CI watch — Atom
- CHF 5188 pMDI CI watch — JSON
- CHF 5188 pMDI alone — RSS
Cite this brief
Drug Landscape (2026). CHF 5188 pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/chf-5188-pmdi. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing